Back to top
more

ADMA Biologics (ADMA)

(Delayed Data from NSDQ)

$9.21 USD

9.21
3,628,371

+0.15 (1.66%)

Updated May 17, 2024 04:00 PM ET

After-Market: $9.24 +0.03 (0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Novavax (NVAX) is expected to provide updates on its ongoing clinical development in the first quarter of 2023.

Bellerophon (BLPH) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Bellerophon (BLPH) is expected to provide updates on its proprietary INOpulse platform, being developed for treating several pulmonary hypertension indications, on its first-quarter earnings call.

Here's Why You Should Add Allogene (ALLO) Stock to Your Portfolio

by Zacks Equity Research

Allogene Therapeutics (ALLO), a top-ranked stock, is currently focused on developing allogenic CAR T therapies for treating cancer.

Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data

by Zacks Equity Research

Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.

Agenus (AGEN) Rises on Fast Track Tag for Cancer Combo Drug

by Zacks Equity Research

The FDA grants Fast Track Designation to Agenus' (AGEN) phase II study evaluating the botensilimab/balstilimab combination in non-MSI-H colorectal cancer patients. The stock jumps 16% following the news.

Aeglea (AGLE) Plunges 26% After Rare Disorder Drug Study Fails

by Zacks Equity Research

Aeglea BioTherapeutics (AGLE) announces failure to meet goals in the phase I/II study of pegtarviliase for the treatment of Classical Homocystinuria. The stock is down 26% following the news.

Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSK

by Zacks Equity Research

Adaptimmune Therapeutics (ADAP) enters into a transition deal with GSK to regain rights to its proprietary T-cell therapy programs. Shares of the company surges 7% following the news.

Horizon's (HZNP) Tepezza Meets Goals in TED Expanded Use Study

by Zacks Equity Research

Horizon Therapeutics (HZNP) announces positive top-line data from its phase IV study of Tepezza to expand its indication to include TED in adult patients with chronic/low clinical activity scores.

Here's Why You Should Add Acadia (ACAD) Stock to Your Portfolio

by Zacks Equity Research

Acadia (ACAD), a top-ranked stock at present, is witnessing steady growth in Nuplazid sales since its launch. The newly approved drug, Daybue, is set to provide an incremental stream of revenues.

Phathom (PHAT) Up 8% on Erosive Esophagitis Drug's CRL Update

by Zacks Equity Research

Phathom Pharmaceuticals (PHAT) announces a regulatory update regarding vonoprazan for the treatment of erosive esophagitis and H. pylori infection. Stock surges 8% following the news.

Seagen's (SGEN) Padcev & Keytruda Combo Gets FDA Accelerated Nod

by Zacks Equity Research

The FDA grants accelerated approval to Seagen (SGEN) and partner, Astellas' combination therapy of Padcev with Merck's Keytruda for the treatment of first and second-line metastatic urothelial cancer.

Apellis (APLS) Kindles Acquisition Interest Per Bloomberg

by Zacks Equity Research

Per a Bloomberg article, Apellis Pharmaceuticals (APLS) is considering a possible buyout by larger pharma companies.

Avidity (RNA) Down on Update From Neuromuscular Disease Study

by Zacks Equity Research

Avidity Biosciences (RNA) provides an update on its phase I/II study of its lead product candidate AOC 1001 for the treatment of myotonic dystrophy type I. The stock falls about 17%.

Adma Biologics (ADMA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adma Biologics (ADMA) delivered earnings and revenue surprises of 14.29% and 1.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 5.56% and 41.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Mesoblast's (MESO) GVHD Drug BLA Gets FDA Priority Tag, Stock Up

by Zacks Equity Research

Mesoblast (MESO) announces the FDA acceptance for review of the resubmitted biological license application for remestemcel-L for the treatment of children under 12 with steroid-refractory acute graft versus host disease. Stock gains on Wednesday, following the news.

Merck (MRK) Reports Detailed Data From PAH Study on Sotatercept

by Zacks Equity Research

Merck & Co. (MRK) announces detailed data from the phase III STELLAR study of sotatercept for the treatment of pulmonary arterial hypertension in adults.

Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -31.71% and 89.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Horizon's (HZNP) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) reports better-than-expected fourth-quarter 2022 results as it beats the Zacks Consensus Estimate for both revenues and earnings.

Intra-Cellular (ITCI) Q4 Earnings & Sales Top, Caplyta Shines

by Zacks Equity Research

Intra-Cellular Therapeutics (ITCI) reports a better-than-expected financial performance in the fourth quarter of 2022 as both earnings and revenues beat estimates.

Allogene (ALLO) Incurs Narrower-Than-Expected Loss in Q4

by Zacks Equity Research

Allogene's (ALLO) fourth-quarter earnings beat estimates but sales come in line.

Novavax (NVAX) Q4 Earnings & Revenues Miss Estimates, Stock Down

by Zacks Equity Research

Novavax (NVAX) reports worse-than-expected financial performance in the fourth quarter of 2022, with earnings and revenues both missing the Zacks Consensus Estimate. Stock plunges 26.1% in response to the news.

Acadia (ACAD) Q4 Earnings Miss, Nuplazid Sales Boost Revenues

by Zacks Equity Research

Acadia Pharmaceuticals (ACAD) reports mixed results for the fourth quarter of 2022, recording wider-than-expected loss per share and better-than-expected revenue figures owing to the sales of Nuplazid.

BioMarin (BMRN) Q4 Earnings Miss, Sales Beat, Stock Down

by Zacks Equity Research

BioMarin (BMRN) reports mixed Q4 results as it misses estimates for earnings but beats the same for sales. Its 2023 sales guidance falls short slightly

Seagen (SGEN) Likely to be Acquired by Pfizer Claims WSJ

by Zacks Equity Research

Seagen (SGEN) may be acquired by the large-cap pharma company Pfizer at a valuation of more than $30 billion, according to a Wall Street Journal article. Seagen's stock is up 17% in pre-market hours in response to the news.